This is the first update to the original CTS communication distributed on July 6th. As previously communicated, all CTS healthcare partners will remain on the Grifols ZIKV clinical trial until at least the end of October 2018, which coincides with the end of the WNV season.
Check out the Communication page for the complete details on the NAT ZIKV test update or by clicking the link: Communications
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization